Navigation Links
Nano shake-up
Date:4/14/2014

Significant advances have been made in chemotherapy over the past decade, but targeting drugs to cancer cells while avoiding healthy tissues continues to be a major challenge.

Nanotechnology has unlocked new pathways for targeted drug delivery, including the use of nanocarriers, or capsules, that can transport cargoes of small-molecule therapeutics to specific locations in the body.

The catch? These carriers are tiny, and it matters just how tiny they are. Change the size from 10 nanometers to 100 nanometers, and the drugs can end up in the wrong cells or organs and thereby damage healthy tissues.

A common assumption is that once a nanocarrier is created, it maintains its size and shape on the shelf as well as in the body.

However, recent work by a group of researchers led by Thomas H. Epps, III, and Millicent Sullivan in the Department of Chemical and Biomolecular Engineering at the University of Delaware has shown that routine procedures in handling and processing nanocarrier solutions can have a significant influence on the size and shape of these miniscule structures.

Their findings are reported in a paper, "Size Evolution of Highly Amphiphilic Macromolecular Solution Assemblies Via a Distinct Bimodal Pathway," published in Nature Communications on April 7.

Sullivan explains that chemotherapeutic agents are designed to affect processes related to cell division. Therefore, they not only kill cancer cells but also are toxic to other rapidly proliferating cells such as those in hair follicles and bone marrow. Side effects can range from hair loss to compromised immune systems.

"Our goal is to deliver drugs more selectively and specifically to cancer cells," Sullivan says. "We want to sequester the drug so that we can control when and where it has an impact."

Although there are a number of routes to creating drug-carrying nanocapsules, there is growing interest in the use of polymers for this application.

"Molecular self-assembly of polymers offers the ability to create uniform, tailorable structures of predetermined size and shape," Epps says. "The problem lies in assuming that once they're produced, they don't change."

It turns out that they do change, and very small changes can have a very large impact.

"At 75 nanometers, a nanocarrier may deliver its cargo directly to a tumor," Epps says. "But with vigorous shaking, it can grow to 150 nanometers and may accumulate in the liver or the spleen. So simple agitation can completely alter the distribution profile of the nanocarrier-drug complex in the body."

The work has significant implications for the production, storage, and use of nano-based drug delivery systems.

About the research

The researchers used a variety of experimental techniques including cryogenic transmission electron microscopy (cryo-TEM), small angle X-ray scattering (SAXS), small angle neutron scattering (SANS), and dynamic light scattering (DLS) to probe the effects of common preparation conditions on the long-term stability of the self-assembled structures.

The work was carried out in collaboration with the University's Center for Neutron Science and the National Institute of Standards and Technology Center for Neutron Research.

The paper was co-authored by Elizabeth Kelley, Ryan Murphy, Jonathan Seppala, Thomas Smart, and Sarah Hann.

Thomas H. Epps, III, is the Thomas and Kipp Gutshall Chair of Chemical and Biomolecular Engineering, and Millicent Sullivan is an associate professor in the Department of Chemical and Biomolecular Engineering.


'/>"/>

Contact: Andrea Boyle Tippett
aboyle@udel.edu
302-831-1421
University of Delaware
Source:Eurekalert  

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nano shake-up
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: